Anthracyclines such as daunorubicin and doxorubicin are an important class of drugs in many malignancies. However, their use is significantly limited by cardiotoxicity. Previous studies have suggested that a liposomal formulation of doxorubicin can mitigate this toxicity. Marie Fortin, PhD, Jazz Pharmaceuticals, Palo Alto, CA, discusses the results of a pre-clinical study evaluating the cardiotoxicity of CPX-351, a liposomal formulation of cytarabine and daunorubicin, on human induced pluripotent stem cell (iPSC)-derived cardiomyocytes. After proving that the in vitro iPSC-derived cardiomyocyte model was able to detect the difference between free and liposomal doxorubicin, showing that cardiotoxicity was mitigated in cells treated with liposomal doxorubicin, the study further demonstrated that CPX-351 mitigated cardiotoxicity in a similar fashion when applied at an equivalent concentration and on the same schedule. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
